Dergiler / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 3

Efficacy and Safety of Catheter Ablation Combined with Left Atrial Appendage Closure in the Treatment of Atrial Fibrillation: A Systematic Review and Meta-Analysis

Sayfa
154–162
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Catheter ablation combined with left atrial appendage closure appears to have longer procedure and fluoroscopy times than catheter ablation alone.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Catheter ablation combined with left atrial appendage closure is effective in treating atrial fibrillation.
📊
Temel Bulgular & Veri:These studies reported at least one of the following outcomes: the freedom from atrial arrhythmia rate, the procedure time, the fluoroscopy time, perioperative complications, thromboembolic events, and bleeding events during follow-up.
💡
Sonuç & Katkı:Catheter ablation combined with left atrial appendage closure appears to have longer procedure and fluoroscopy times than catheter ablation alone.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Catheter ablation combined with left atrial appendage closure is effective in treating atrial fibrillation. However, the effectiveness of this combined treatment compared with catheter ablation alone is still controversial. Methods: We searched studies in databases, including The Cochrane Library, PubMed, EMBASE, and Web of Science, that compared catheter ablation combined with left atrial appendage closure and catheter ablation alone in the treatment of atrial fibrillation. These studies reported at least one of the following outcomes: the freedom from atrial arrhythmia rate, the procedure time, the fluoroscopy time, perioperative complications, thromboembolic events, and bleeding events during follow-up. The risk ratio and standard mean difference with 95% CI were analyzed by the random-effects model. Results: Five studies involving 699 people were included in our meta-analysis. We found no significant difference in the freedom from atrial arrhythmia rate (risk ratio = 0.93, 95% CI = 0.83-1.04, I2 = 0%, P = .21) between the 2 groups. Catheter ablation combined with left atrial appendage closure showed significantly longer procedure and fluoroscopy times than catheter ablation alone (standard mean difference = 1.26, 95% CI = 0.85-1.67, P < .00001 and standard mean difference = 1.19, 95% CI = 0.53-1.85, P = .0004, respectively). With regard to safety outcomes, no significant differences were observed in perioperative complications (RR = 1.62, 95% CI = 0.99-2.63, I2 = 0%, P = .05), thromboembolic events (RR = 0.67, 95% CI = 0.15-3.11, I2 = 0%, P = .61), or bleeding events (RR = 0.67, 95% CI = 0.11-3.88, P = .65) between the 2 groups during follow-up. Conclusion: The freedom from atrial arrhythmia rate and safety outcomes of catheter ablation combined with left atrial appendage closure are similar to those of catheter ablation alone. Catheter ablation combined with left atrial appendage closure appears to have longer procedure and fluoroscopy times than catheter ablation alone.

🔖

Bu Makaleye Atıf Yap

WANG, A., JIANG, J., XIE, Z. (2022). Efficacy and Safety of Catheter Ablation Combined with Left Atrial Appendage Closure in the Treatment of Atrial Fibrillation: A Systematic Review and Meta-Analysis. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 3, 154–162. https://ajindex.com/articles/407424

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Chung MK, Refaat M, Shen WK, et al. Atrial fibrillation: JACC council perspectives. J Am Coll Cardiol. 2020
  2. 75(14):1689-1713. [CrossRef] 2. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006
  3. 9(5):348-356. [CrossRef] 3. Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019
  4. 321(11):1059-1068. [CrossRef] 4. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients With atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019
  5. 321(13):1275-1285. [CrossRef] 5. Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020
  6. Mao YJ, Wang H, Chen JX, Huang PF. Meta-analysis of medical management versus catheter ablation for atrial fibrillation. Rev Cardiovasc Med. 2020
  7. 21(3):419-432. [CrossRef] 7. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) expert consensus statement on left atrial appendage closure in the prevention of stroke in patients with atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi. 2019
  8. 47(12):937-955. [CrossRef] 8. Pallazola VA, Kapoor RK, Kapoor K, McEvoy JW, Blumenthal RS, Gluckman TJ. Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: a clinical review. Vasc Med. 2019
  9. 24(2):141-152. [CrossRef] 9. Gebreyohannes EA, Salter S, Chalmers L, Bereznicki L, Lee K. Non-adherence to thromboprophylaxis guidelines in atrial fibrillation: a narrative review of the extent of and factors in guideline non-adherence. Am J Cardiovasc Drugs. 2021
  10. 21(4):419-433. [CrossRef] 10. Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015
  11. 73(3-4):184- 191. [CrossRef] 11. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011